Skip to main content
SpringerLink
Log in

Drug-Induced Pisa Syndrome (Pleurothotonus)

Epidemiology and Management

  • Therapy in Practice
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Long-term administration of antipsychotics occasionally produces persistent dystonia of the trunk, a disorder known as Pisa syndrome (or pleurothotonus). The development of Pisa syndrome is most commonly associated with prolonged treatment with antipsychotics; however, it has also been reported, although less frequently, in patients who are receiving other medications (such as cholinesterase inhibitors and antiemetics), in those not receiving medication (idiopathic Pisa syndrome) and in those with neurodegenerative disorders.

Drug-induced Pisa syndrome predominantly develops in females and in older patients with organic brain changes. It sometimes occurs after the addition of another antipsychotic to an established regimen of antipsychotics or insidiously arises in antipsychotic-treated patients for no apparent reason. The condition generally disappears after antipsychotic drugs are discontinued. Although a pharmacological therapy for drug-induced Pisa syndrome has not been established, we have reported that anticholinergic drugs are effective in about 40% of patients who have episodes of Pisa syndrome with the remaining patients responding to the withdrawal or reduction of daily doses of antipsychotic drugs.

The characteristics of its development and prognosis indicate that druginduced Pisa syndrome consists of two types of dystonia. Some patients develop clinical features of acute dystonia, whereas others develop symptoms similar to tardive dystonia. Like that of tardive dystonia, Pisa syndrome responds better than tardive dyskinesia to a relatively high daily dose of an anticholinergic. However, the significant improvement caused by the withdrawal of antipsychotic drugs in Pisa syndrome differentiates it from tardive dystonia. Thus, Pisa syndrome including these features is considered to be an atypical type of tardive dystonia.

These clinical characteristics suggest that the underlying pathophysiology of drug-induced Pisa syndrome is complex. A dopaminergic-cholinergic imbalance, or serotonergic or noradrenergic dysfunction, may be implicated. Asymmetric brain functions or neural transmission may also be considered as underlying mechanisms of the development of Pisa syndrome that is resistant to anticholinergic drugs.

Idiopathic Pisa syndrome is characterised by an adult-onset, segmental truncal dystonia in patients with no previous exposure to antipsychotics. It occurs rarely but shows a complete resolution with high doses of anticholinergic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–60

    Article  PubMed  CAS  Google Scholar 

  2. Keegan DL, Rajput AH. Drag induced dystonia tarda: treatment with L-dopa. Dis Nerv Syst 1973; 34: 167–9

    PubMed  CAS  Google Scholar 

  3. Fahn S, Jankovic J. Practical management of dystonia. Neurol Clin 1984; 2: 555–69

    PubMed  CAS  Google Scholar 

  4. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drags. Neurology 1982; 32: 1335–46

    Article  PubMed  CAS  Google Scholar 

  5. Jeste DV, Wisniewski AA, Wyatt RJ. Neuroleptic-associated tardive syndromes. Psychiatr Clin North Am 1986; 9: 183–92

    PubMed  CAS  Google Scholar 

  6. Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972; 202: 94–103

    Article  PubMed  CAS  Google Scholar 

  7. Yassa R. The Pisa syndrome: a report of two cases. Br J Psychiatry 1985; 146: 93–5

    Article  PubMed  CAS  Google Scholar 

  8. Saxena S. Tardive dystonia and Pisa syndrome [letter]. Br J Psychiatry 1986; 149: 524

    Article  PubMed  CAS  Google Scholar 

  9. Guy N, Raps A, Assael M. The Pisa syndrome during maintenance antipsychotic therapy [letter]. Am J Psychiatry 1986; 143: 1492

    PubMed  CAS  Google Scholar 

  10. Pilette WL. Pisa syndrome, or pleurothotonus. Am J Psychiatry 1987; 144: 969–70

    PubMed  CAS  Google Scholar 

  11. Amore M, Cerisoli M, Campanile S, et al. Pisa syndrome: report of a case. Ital J Neurol Sci 1988; 9: 273–4

    Article  PubMed  CAS  Google Scholar 

  12. Davidson M, Powchik P, Davis KL. Pisa syndrome in Alzheimer’s disease [letter]. Biol Psychiatry 1988; 23: 213

    Article  PubMed  CAS  Google Scholar 

  13. Remington GJ. The Pisa syndrome: possible role for serotonin and noradrenaline. J Clin Psychopharmacol 1988; 8: 228–9

    Article  PubMed  CAS  Google Scholar 

  14. Chiu HFK, Li SW, Lee S. Pisa syndrome in a Chinese patient. Aust N Z J Psychiatry 1989; 23: 127–8

    Article  PubMed  CAS  Google Scholar 

  15. Suzuki T, Koizumi J, Moroji T, et al. Clinical characteristics of the Pisa syndrome. Acta Psychiatr Scand 1990; 82: 454–7

    Article  PubMed  CAS  Google Scholar 

  16. Turk J, Lask B. Pisa syndrome in an adolescent on neuroleptic medication. Br J Psychiatry 1991; 158: 422–3

    Article  PubMed  CAS  Google Scholar 

  17. Suzuki E, Kanba S, Nibuya M, et al. Use of pimozide in the Pisa syndrome. Am J Psychiatry 1992; 149: 1114–5

    PubMed  CAS  Google Scholar 

  18. Fichtner CG, Pechter BM, Jobe TH. Pisa syndrome mistaken for conversion in an adolescent. Br J Psychiatry 1992; 161: 849–52

    Article  PubMed  CAS  Google Scholar 

  19. Garcia C. Pisa-syndrom. Nervenarzt 1992; 63: 434–9

    PubMed  CAS  Google Scholar 

  20. Kurtz G, Kapfhammer HP, Peuker B. Pisa-syndrome unter clozapintherapie. Nervenarzt 1993; 64: 742–6

    PubMed  CAS  Google Scholar 

  21. Suzuki T, Kurita H, Hori T, et al. The Pisa syndrome (pleurothotonus) during antidepressant therapy. Biol Psychiatry 1997; 41: 234–6

    Article  PubMed  CAS  Google Scholar 

  22. Diez-Martin JM. The Pisa syndrome as another acute dystonia subtype. J Drug Dev Clin Pract 1995; 7: 59–61

    Google Scholar 

  23. Padberg F, Stubner S, Buch K, et al. Pisa syndrome during treatment with sertindole. Br J Psychiatry 1998; 173: 351–2

    Article  PubMed  CAS  Google Scholar 

  24. Bruneau MA, Stip E. Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment. Int Clin Psychopharmacol 1998; 13: 229–32

    Article  PubMed  CAS  Google Scholar 

  25. Suzuki T, Hori T, Baba A, et al. Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome). J Clin Psychopharmacol 1999; 19: 277–80

    Article  PubMed  CAS  Google Scholar 

  26. Kwak YT, Han I-W, Baik J, et al. Relation between cholinesterase inhibitor and Pisa syndrome [letter]. Lancet 2000; 355:2222

    Article  PubMed  CAS  Google Scholar 

  27. Bhattacharya KF, Giannakikou I, Munroe N, et al. Primary anticholinergic-responsive Pisa syndrome. Mov Disord 2000; 15: 1285–6

    Article  PubMed  CAS  Google Scholar 

  28. Miyaoka T, Seno H, Yamamoti C, et al. Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. J Clin Psychiatry 2001; 62: 573–4

    Article  PubMed  CAS  Google Scholar 

  29. Yassa R, Nastase C, Cvejic J, et al. The Pisa syndrome (or pleurothotonus): prevalence in a psychogeriatric population. Biol Psychiatry 1990; 29: 942–5

    Article  Google Scholar 

  30. Stubner S, Padberg F, Grohmann R, et al. Pisa syndrome (pleurothotonus): report of a multicenter drag safety surveillance project. J Clin Psychiatry 2000; 61: 569–74

    Article  PubMed  CAS  Google Scholar 

  31. Patel S, Tariot PN, Hamill RW. Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1991; 4: 48–51

    Article  PubMed  CAS  Google Scholar 

  32. Colosimo C. Pisa syndrome in a patient with multiple system atrophy. Mov Disord 1998; 13: 607–9

    Article  PubMed  CAS  Google Scholar 

  33. Bhatia KP, Quinn NP, Marsden CD. Clinical features and natural history of axial predominant adult onset primary dystonia. J Neurol Neurosurg Psychiatry 1997; 63: 788–91

    Article  PubMed  CAS  Google Scholar 

  34. Fichtner CG. Pleurothotonus and the Pisa syndrome [letter]. Biol Psychiatry 1992; 31: 534

    Article  PubMed  CAS  Google Scholar 

  35. Van Harten PR. Pisa syndrome — a confusing term. Br J Psychiatry 1992; 160: 424–5

    Article  PubMed  Google Scholar 

  36. Wolf ME, Koller WC. Tardive dystonia: treatment with trihexyphenidyl. J Clin Psychopharmacol 1985; 5: 247–8

    Article  PubMed  CAS  Google Scholar 

  37. Lieberman J, Lesser M, Johns C, et al. Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol 1988; 8Suppl. 4: 57S–63S

    PubMed  CAS  Google Scholar 

  38. Wojcik JD, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991; 148: 1055–9

    PubMed  CAS  Google Scholar 

  39. Raja M. Tardive dystonia. Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients. Eur Arch Psychiatry Clin Neurosci 1995; 245: 145–51

    CAS  Google Scholar 

  40. Gimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand 1985; 71:488–94

    Article  PubMed  CAS  Google Scholar 

  41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: American Psychiatric Association, 1994

    Google Scholar 

  42. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352–3

    Google Scholar 

  43. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152: 122–5

    PubMed  CAS  Google Scholar 

  44. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1: 193–208

    Article  PubMed  CAS  Google Scholar 

  45. Gardos G, Cole JO, Salomon M, et al. Clinical forms of severe tardive dyskinesia. Am J Psychiatry 1987; 144: 895–902

    PubMed  CAS  Google Scholar 

  46. Yassa R, Nair NPV, Iskandar H, et al. Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry 1990; 147: 1156–63

    PubMed  CAS  Google Scholar 

  47. Fahn S. Drag treatment of hyperkinetic movement disorders. Semin Neurol 1987; 7: 192–208

    Article  PubMed  CAS  Google Scholar 

  48. Luchins DJ, Goldman M. High-dose bromocriptine in a case of tardive dystonia. Biol Psychiatry 1985; 20: 179–81

    Article  PubMed  CAS  Google Scholar 

  49. Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J Nerv Ment Dis 1993; 181: 137–8

    Article  PubMed  CAS  Google Scholar 

  50. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10

    Article  PubMed  CAS  Google Scholar 

  51. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983;33:1255–61

    Article  PubMed  CAS  Google Scholar 

  52. Yadalam KG, Korn ML, Simpson GM. Tardive dystonia: four cases histories. J Clin Psychiatry 1990; 51: 17–20

    PubMed  CAS  Google Scholar 

  53. Tan CH, Tay LK. Tardive dyskinesia in elderly psychiatric patients in Singapore. Aust N Z J Psychiatry 1991;25: 119–22

    Article  PubMed  CAS  Google Scholar 

  54. Chiu H, Shum P, Lau J, et al. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 1992; 149: 1081–5

    PubMed  CAS  Google Scholar 

  55. Garver DL, Davis JM, Dekirmenjian H, et al. Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacology 1976; 47: 199–201

    Article  CAS  Google Scholar 

  56. Tollefson GD. Antidepressant treatment and side effect considerations. J Clin Psychiatry 1991; 52 Suppl. 5: 4–13

    Google Scholar 

  57. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991; 52(6 Suppl.): 4–10

    PubMed  Google Scholar 

  58. Povlsen UJ, Noring U, Lund LA. Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys. Clin Neuropharmacol 1986; 9: 84–90

    Article  PubMed  CAS  Google Scholar 

  59. Bleich A, Brown S, Kahn R. The role of serotonin in schizophrenia. Schizophr Bull 1988; 14: 297–315

    Article  PubMed  CAS  Google Scholar 

  60. Arya DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994; 165: 728–33

    Article  PubMed  CAS  Google Scholar 

  61. Casey DE. Dopaminergic and serotonergic aspects of acute extrapyramidal syndromes. Psychopharmacol Ser 1993; 10: 101–10

    PubMed  CAS  Google Scholar 

  62. Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987; 50: 801–3

    Article  PubMed  CAS  Google Scholar 

  63. Myslobodsky M. Pharmacologic implications of hemispheric asymmetry. Life Sci 1976; 19: 1467–78

    Article  PubMed  CAS  Google Scholar 

  64. Oke A, Keller R, Mefford I, et al. Lateralization of norepinephrine in human thalamus. Science 1978; 200: 1411–3

    Article  PubMed  CAS  Google Scholar 

  65. Glick SD, Ross DA, Hough LB. Lateral asymmetry of neurotransmitters in human brain. Brain Res 1982; 234: 53–63

    Article  PubMed  CAS  Google Scholar 

  66. Tomer R, Mintz M, Myslobodsky MS. Left hemisphere hyperactivity in schizophrenia: abnormality inherent to psychosis or neuroleptic side-effects? Psychopharmacology 1982; 77: 168–70

    Article  PubMed  CAS  Google Scholar 

  67. Reynolds GP. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 1983; 305: 527–9

    Article  PubMed  CAS  Google Scholar 

  68. Farde L, Wiesel FA, Hall H, et al. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987; 44: 671–2

    Article  PubMed  CAS  Google Scholar 

  69. Arato M, Frecska E, Tekes K, et al. Serotonergic interhemispheric asymmetry: gender difference in the orbital cortex. Acta Psychiatr Scand 1991; 84: 110–1

    Article  PubMed  CAS  Google Scholar 

  70. Martin JP. Curvature of the spine in post-encephalitic parkinsonism. J Neurol Neurosurg Psychiatry 1965; 28: 395–400

    Article  PubMed  CAS  Google Scholar 

  71. Duvoisin RC, Marsden CD. Note on the scoliosis of parkinsonism. J Neurol Neurosurg Psychiatry 1975; 38: 787–93

    Article  PubMed  CAS  Google Scholar 

  72. Garnett ES, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 1984; 11: 174–9

    PubMed  CAS  Google Scholar 

  73. Perlmutter JS, Raichle ME. Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. Ann Neurol 1984; 15: 228–33

    Article  PubMed  CAS  Google Scholar 

  74. Trabucchi M, Albizzati MG, Frattola L, et al. Hemiparkinsonism: a human model for studying dopaminergic supersensitivity. Arch Neurol 1979; 36: 246–8 Correspondence and offprints: Dr Toshihito Suzuki, Department of Psychiatry, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Toshihito Suzuki

  2. Mitsukaido Kosei Hospital, Mitsukaido, Ibaraki, Japan

    Hisashi Matsuzaka

Authors
  1. Toshihito Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hisashi Matsuzaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshihito Suzuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suzuki, T., Matsuzaka, H. Drug-Induced Pisa Syndrome (Pleurothotonus). Mol Diag Ther 16, 165–174 (2002). https://doi.org/10.2165/00023210-200216030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200216030-00003

Keywords

Search

Navigation